Bing Wang
Bing Wang publishes mostly in Molecular Biology, Oncology and Immunology, on topics such as Lignin and Wood Chemistry, CAR-T cell therapy research and PARP inhibition in cancer therapy.
- World rank
- #1,389,654 of 7,710,434 ranked researchers
- Rank in China
- #205,225 of 978,568
- Works
- 248
- Citations
- 4.9k
- Citations per work
- 19.7
What does Bing Wang research?
Bing Wang's work is mostly in Biochemistry, Genetics and Molecular Biology (22%), Medicine (16%), Immunology and Microbiology (5%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Everything else12148.9%
- Life Sciences6727.1%
- Health Sciences3915.6%
- Medicine3915.6%
- Physical Sciences218.4%
- Chemistry124.8%
- Engineering93.6%
- 1Molecular Biology19% of their works
- 2Oncology16% of their works
- 3Immunology5% of their works
- 4Organic Chemistry5% of their works
- 5Biomedical Engineering4% of their works
- 6Cell Biology3% of their works
Research topics
Which keywords describe Bing Wang's research?
The keywords of their largest research topics: Cancer Therapy, Homologous Recombination, Immunotherapy, CAR T Cells, Catalytic Transformation, Chimeric Antigen Receptor, Lignin Valorization and BRCA Mutation.
- Hemoglobin
- Multidrug Resistance
- ATP-dependent Transporters
- Repair
- Cell Cycle
- BRCA Mutation
- Chimeric Antigen Receptor
- CAR T Cells
- Homologous Recombination
- Cancer Therapy
- Immunotherapy
- Catalytic Transformation
- Lignin Valorization
- PARP Inhibitors
- DNA Damage
- p53
- Genomic Profiles
- Small-Cell Lung Cancer
- Scavenger Receptor
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 19 words, with their numbers
- Cancer Therapy212 topics
- Homologous Recombination212 topics
- Immunotherapy202 topics
- CAR T Cells121 topic
- Catalytic Transformation121 topic
- Chimeric Antigen Receptor121 topic
- Lignin Valorization121 topic
- BRCA Mutation111 topic
- PARP Inhibitors111 topic
- Cell Cycle101 topic
- DNA Damage101 topic
- Repair101 topic
- p53101 topic
- ATP-dependent Transporters81 topic
- Genomic Profiles81 topic
- Multidrug Resistance81 topic
- Small-Cell Lung Cancer81 topic
- Hemoglobin71 topic
- Scavenger Receptor71 topic
Where does Bing Wang work?
Bing Wang's main affiliation in the publication record is Beijing Forestry University, China.
How many publications and citations does Bing Wang have?
OpenAlex counts 248 works and 4,894 citations for Bing Wang, an h-index of 40, ranking #1,389,654 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Other researchers named Bing Wang
- bing-wang-anhui-university-of-technology
- bing-wang-shandong-university
- bing-wang-chinese-academy-of-sciences-china
- bing-wang-chinese-academy-of-sciences
- bing-wang-university-of-science-and-technology-of-china
- bing-wang-huazhong-university-of-science-and-technology
- bing-wang-charles-sturt-university
- bing-wang-chinese-academy-of-sciences-china-2
- bing-wang-sichuan-university
- bing-wang-harbin-institute-of-technology
- bing-wang-liaoning-university-of-traditional-chinese-medicine
- bing-wang-zhejiang-university
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Bing Wang. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.